ReviewFrontiers in oncology2022
Current concepts of anti-EGFR targeting in metastatic colorectal cancer.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2024Pooled it
- Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers · 2026Review
- Immunotherapy resistance in colorectal cancer: therapeutic strategies and biomarker-guided approaches.Cancer cell international · 2026Review
- Extracellular signalling regulates gastrin transcription through site-specific phosphorylation and nuclear redistribution of Menin.bioRxiv : the preprint server for biology · 2026Article
- Targeting cell death: a promising approach for colorectal cancer therapy.Cancer cell international · 2026Review
- Emerging Molecular Insights and Targeted Therapeutics in Colorectal Cancer: From Emerging Approaches to Personalized Medicine.Journal of gastrointestinal cancer · 2026Review
- EGFR-targeted tyrosine kinase inhibitors: advancements in cancer therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Development and in vitro evaluation of liposomes and immunoliposomes containing 5-fluorouracil and R-phycoerythrin as a potential phototheranostic system for colorectal cancer.Beilstein journal of nanotechnology · 2026Article
- The Multifaceted Role of Annexin A1 in Colorectal Cancer: From Molecular Mechanisms to Predictive and Prognostic Implications.Medical sciences (Basel, Switzerland) · 2025Review
- An Update on Cutaneous Metastases of Internal Malignancies.Medicina (Kaunas, Lithuania) · 2025Review
- Circulating tumor DNA for MRD detection in colorectal cancer: recent advances and clinical implications.Biomarker research · 2025Review
- Molecular and Immunohistochemical Biomarkers in Colorectal Carcinoma - A Single Center Study.Balkan journal of medical genetics : BJMG · 2025Article
- Systemic Therapy for Metastatic Colon Cancer: New Frontiers.Clinics in colon and rectal surgery · 2025Review
- Pan-immune-inflammation in colon cancer: A prognostic biomarker and the role of tumor location in personalized care.World journal of gastrointestinal surgery · 2025Article
- Multifaceted Approaches in Epithelial Cell Adhesion Molecule-Mediated Circulating Tumor Cell Isolation.Molecules (Basel, Switzerland) · 2025Review
- NOS2/ARG1 axis and immune cell ratios as promising prognostic and predictive biomarkers for Cetuximab combined with chemotherapy in wt-KRAS human colorectal cancer.Frontiers in immunology · 2025Article
- Predictive role of [EJNMMI reports · 2024Article
- USP21-EGFR signaling axis is functionally implicated in metastatic colorectal cancer.Cell death discovery · 2024Article
- Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response.International journal of molecular sciences · 2024Review
- Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-EGFR targeting is one of the key strategies in the treatment of metastatic colorectal cancer (mCRC). For almost two decades oncologists have struggled to implement EGFR antibodies in the mCRC continuum of care. Both sidedness and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.